P. Merle

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette et al. · Journal of Thoracic Oncology · 2019 · 181 citations · Full text

Medicine, Pharmacology, Pathology +8

Circulating free DNA concentration is an independent prognostic biomarker in lung cancer

Claire Tissot, Anne‐Claire Toffart, Stéphanie Villar et al. · European Respiratory Journal · 2015 · 150 citations · Full text

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Solange Peters, Jean-Louis Pujol, Urania Dafni et al. · Annals of Oncology · 2021 · 105 citations · Full text

Oncology, Immune Checkpoint Inhibitor, Consolidation Nivolumab +6

Preoperative respiratory muscle endurance training improves ventilatory capacity and prevents pulmonary postoperative complications after lung surgery

Hélène Laurent, Sylvie Aubreton, Géraud Galvaing et al. · European Journal of Physical and Rehabilitation Medicine · 2020 · 70 citations

Customized Adjuvant Phase II Trial in Patients With Non–Small-Cell Lung Cancer: IFCT-0801 TASTE

Marie Wislez, Fabrice Barlési, Benjamin Besse et al. · Journal of Clinical Oncology · 2014 · 65 citations · Full text